Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Apr 17;16(4):e58482.
doi: 10.7759/cureus.58482. eCollection 2024 Apr.

A Clinical Study of Intraoperative Perfusion Chemotherapy in Gastric Cancer: A Prospective Cohort Study

Sohail Ahmed  1 , Muhammad Amir  2 , Khan Adnan  1 , Zhang Zilong  3 , Amna Akbar  4 , Sania Khan  5 , Sarosh Khan Jadoon  6 , Mohammad Saleem Khan  7
Affiliations

A Clinical Study of Intraoperative Perfusion Chemotherapy in Gastric Cancer: A Prospective Cohort Study

Sohail Ahmed et al. Cureus. .

Abstract

Introduction: Gastric cancer (GC) is the third largest cause of cancer-related death worldwide, with major geographic disparities in incidence and outcomes. Sociodemographic indicators, food habits, and genetic predispositions all add to the load. Despite advances in systemic treatments, peritoneal metastasis remains a concern, with intraperitoneal chemotherapy (IPC) emerging as a promising treatment option.

Methods: A prospective cohort research was done, with 30 GC patients receiving cytoreductive surgery (CRS) followed by lobaplatin-based intraoperative chemotherapy. The study evaluated postoperative complications, survival rates, and disease recurrence using Statistical Package for the Social Sciences (SPSS) version 25.0 (IBM SPSS Statistics, Armonk, NY) for data analysis. The purpose of this study is to assess the effectiveness, safety, and dependability of lobaplatin as an intraoperative chemotherapeutic agent in patients having gastric cancer surgery, with a particular emphasis on those patients who do not have distant metastases.

Results: The study population had a balanced gender distribution, with an average age of 44.83 years. Most patients had advanced-stage cancer (T3 and T4), and lobaplatin treatment resulted in a low frequency of serious postoperative sequelae. Preliminary studies suggest that lobaplatin is a safe and potentially effective IPC drug for GC, with few side effects and adequate survival rates.

Conclusion: Lobaplatin shows promise as an intraoperative chemotherapeutic treatment for gastric cancer, necessitating more research in bigger, randomized controlled studies to determine its efficacy and safety profile. The study emphasizes the need for novel treatment strategies to enhance the prognosis of GC patients, particularly those with peritoneal involvement.

Keywords: chemotherapy; drug efficacy; gastric cancer; intraoperative chemotherapy; lobaplatin.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Frequency of postoperative complications
RFTs: renal function tests, LFTs: liver function tests
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Intraperitoneal chemotherapy in the treatment of gastric cancer peritoneal metastases: an overview of common therapeutic regimens. Brandl A, Prabhu A. J Gastrointest Oncol. 2021;12:0–44. - PMC - PubMed
    1. Gastric cancer, version 2.2022, NCCN Clinical Practice Guidelines in Oncology. Ajani JA, D'Amico TA, Bentrem DJ, et al. J Natl Compr Canc Netw. 2022;20:167–192. - PubMed
    1. The global, regional, and national burden of stomach cancer in 195 countries, 1990-2017: a systematic analysis for the Global Burden of Disease study 2017. Lancet Gastroenterol Hepatol. 2020;5:42–54. - PMC - PubMed
    1. Gastric cancer: epidemiology, risk factors and prevention strategies. Yang L, Ying X, Liu S, et al. Chin J Cancer Res. 2020;32:695–704. - PMC - PubMed
    1. Epidemiology of gastric cancer: global trends, risk factors and prevention. Rawla P, Barsouk A. Prz Gastroenterol. 2019;14:26–38. - PMC - PubMed

LinkOut - more resources